On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 3, 2005, Pages 182-192

  Meno Tetang, Guy M L ^a   Lowe, Philip J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; OMALIZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ATOPIC DERMATITIS; CIRCULATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; LYMPH NODE; LYMPHOCYTE; MALE; MONKEY; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; HALF-LIFE; HUMANS; IMMUNOGLOBULIN E; MACACA FASCICULARIS; MALE; MODELS, BIOLOGICAL; PROPYLENE GLYCOLS; RATS; RATS, WISTAR; SPHINGOSINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15244344037     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto960307.x     Document Type: Conference Paper

References (37)

1. Asher, A., J. J. Mule, C. M. Reichert, E. Shiloni & S. A. Rosenberg: Studies on the anti-tumor efficacy of systemically admistered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 1987, 138, 963-974.
2. Bernareggi, A. & M. Rowland: Physiologic modeling of cyclosporin kinetics in rat and man. J. Pharmacokinet. Biopharm. 1991, 19, 21-50.
3. Blick, M., S. A. Sherwin, M. Rosenblum & J. Gutterman: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987, 47, 2986-2989.
4. Bollon, A. P., S. L. Berent, R. M. Torczynski, N. O. Hill, Y. Lemeshev, J. M. Hill, A. Joher, S. Pichyangkul & A. Khan: Human cytokines, tumor necrosis factor, and interferons: gene cloning, animal studies, and clinical trials. J. Cell Biochem. 1988, 36, 353-367.
5. Casale, T. B., I. L. Bernstein, W. W. Busse, C. F. LaForce, D. G. Tinkelman, R. R. Stoltz, R. J. Dockhorn, J. Reimann, J. Q. Su, R. B. Pick Jr. & D. C. Adelman: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 1997, 100, 110-121.
6. Chapman, P. B., T. J. Lester, E. S. Casper, J. L. Gabrilove, G. Y. Wong, S. J. Kempin, P. J. Gold, S. Welt, R. S. Warren & H. F. Starnes: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J. Clin. Oncol. 1987, 5, 1942-1951.
7. Charles, P., M. J. Elliott, D. Davis, A. Potter, J. R. Kalden, C. Antoni, F. C. Breedveld, J. S. Smolen, G. Eberl, K. deWoody, M. Feldmann & R. N. Maini: Regulation of cytokines, cytokine inhibitors and acute-phase proteins following anti-TNFα therapy in rheumatoid arthritis. J. Immunol. 1999, 163, 1521-1528
8. Chiba, K., Y. Yanagawa, Y. Masubuchi, H. Kataoka, T. Kawaguchi, M. Ohtsuki & Y. Hoshino: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocytes homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 1998, 160, 5037-5044.
9. Creaven, P. J., J. E. Plager, S. Dupere, R. P. Huben, H. Takita, A. Mittelman & A. Proefrock: Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 1987, 20, 137-144.
10. Dayneka, N. L., V. Garg & W. J. Jusko: Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 1993, 21, 457-478.
11. Fahy, J. V., H. E. Fleming, H. H. Wong, J. T. Liu, J. Q. Su, J. Reimann, R. B. Fick Jr. & H. A. Boushey: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Amer. J. Respir. Crit. Care Med. 1997, 155, 1828-1834.
12. FDA http://www.fda.gov/cder/foi/label/2000/inflcen1110991b.pdf.
13. Ferraiolo, B. L., J. A. Moore, D. Crase, P. Gribling, H. Wilking & R. A. Baughman: Pharmacokinetics and tissue distribution of recombinant human tuor necrosis factor-alpha in mice. Drug Metab. Dispos. 1988, 16, 270-275.
14. Flick, D. A. & G. E. Gifford, Pharmacokinetics of murine tumor necrosis factor. J. Immunopharmacol. 1986, 8, 89-97.
15. Gougeon, M.-L.: Apoptosis as an HIV strategy to escape immune attack. Nature Reviews Immunology 2003, 3, 392-404.
16. Haba, S., Z. Ovary & A. Nisonoff: Clearance of IgE from serum of normal and hybridoma-bearing mice. J. Immunol. 1985, 134, 3291-3297.
17. Hanashiro, K., Y. Tokeshi, T. Nakasone, M. Sunagawa, M. Nakamura & T. Kosugi: Analysis of IgE turnover in non-senitized and sensitized rats. Mediators of Inflammation 2001, 10, 217-221.
18. Hirano, T., C. Hom & Z. Ovary: Half-life of murine IgE antibodies in the mouse. Int. Archs. Allergy appl. Immun. 1983, 71, 182-184.
19. Hongshan, L., G. M. L. Meno-Tetang, K. Chiba, N. Arima, P. Heining & W. J. Jusko: Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J. Pharmacol. Exp. Therap. 2002, 301, 519-526.
20. Kawai, R., M. Lemaire, J. L. Steimer, A. Bruelisauer, W. Niederberger & M. Rowland: Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J. Pharmacokin. Biopharm. 1994, 22, 327-65.
21. Kawai, R., D Mathew, C. Tanaka & M. Rowland: Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J. Pharmacol Exp. Therap. 1998, 287, 457-468.
22. Lavé, T., S. Dupin, C. Schmitt, R. C. Chou, D. Jaeck & P. Coassolo: Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J. Pharm. Sci. 1997, 86, 584-590.
23. Lavé, T., P. Coassolo & B. Reigner: Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro - in vivo correlations. Clin. Pharmacokinet. 1999, 36, 211- 231.
24. Lew, K. H., E. A. Ludwig, M. A. Milad, K. Donovan, E. Middleton, J. J. Ferry & W. J. Jusko: Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Therap. 1993, 54, 402-414.
25. Li, H., G. M. L. Meno-Tetang, K. Chiba, N. Arima, P. Heining & W. J. Jusko: Pharmacokinetics and cell trafficking dynamics of 2-amino-2-2[2-(4- octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J. Pharmacol. Exp. Therap. 2002, 301, 519-526.
26. Macallan, D. C., B. Asquith, A. J. Irvine, D. L. Wallace, A. Worth, H. Ghattas, Y. Zhang, G. E. Griffin, D. F. Tough & P. C. Beverley: Measurement and modeling of human T cell kinetics. Eur. J. Immunol. 2003, 33, 2316-2326.
27. Meno-Tetang, G. M. L., H. Li, S. Mis, N. Pyszczynski, P. Heining & W. J. Jusko: Physiologically based pharmacokinetic (PBPK) modeling Of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in rats after single oral and intravenous doses. AAPS Pharm. Sci. 2003, 5, W5262.
28. Mollmann, H., G. Hochhaus, S. Rohatagi, J. Barth & H. Derendorf: Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm. Res. 1995, 12, 1096-1100.
29. Moritz, T., N. Niederle, J. Baumann, D. May, E. Kurschel, R. Osieka, J. Kempeni, E. Schlick & C. G. Schmidt: Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol. Immunother. 1989, 29, 144-150.
30. Rosenblum, M. G., L. Cheung, K. Mujoo & J. L. Murray: An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol. Immunother. 1995, 40, 322-328.
31. Slayter, K. L., E. A. Ludwig, K. H. Lew, E. Jr. Middleton, J. J. Ferry & W. J. Jusko: Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Therap. 1996, 59, 312-321.
32. Taguchi, T.: Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050). Cancer Detect. Prev. 1988, 12, 561-572.
33. Viera, P. & K. Rajewsky: The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol 1988, 18, 313-316.
34. Wald, J. A., R. M. Law, E. A. Ludwig, R. R. Sloan, E. Jr. Middleton & W. J. Jusko: Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J. Pharmacokin. Biopharm. 1992, 20, 567-589.
35. Waldmann, T. A., A. Iio, M. Ogawa, O. R. Mclntyre & W Strober: The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. J. Immunol. 1976, 117, 1139-1144.
36. Yamashita, S. K., E. A. Ludwig, E. Jr. Middleton & W. J. Jusko: Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin. Pharmacol. Therap. 1991, 49, 558-570.
37. Zahn, G. & A. Greischel: Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats. Dose dependence and influence of tumor necrosis factor beta. Arzneimittelforschung 1989, 39, 1180-1182.